Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple‐Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden
Overall, PDL1 expression was low in TNBC cases in our study; however, identifying these cases is important to identify those that can benefit from immunotherapy. We found a significant association of PDL1 expression with neoadjuvant chemotherapy response and RCB. Moreover, PDL1 positivity was associated with lower Ki67 index and older age. Therefore, we recommend routine PDL1 testing in all cases of TNBC to predict neoadjuvant chemotherapy response.
Authors
- Ghazala Mudassir (ORCID: https://orcid.org/0000-0003-0896-5686)
- Umair Arshad Malik (ORCID: https://orcid.org/0000-0002-1713-1889)
- Erum Yousuf Khan
- Atif A Hashmi (ORCID: https://orcid.org/0000-0001-9999-871X)
- Naveen Faridi
- Nur Syahirah Wahid (ORCID: https://orcid.org/0000-0003-4151-5118)
- Syed Muhammad Abu Bakar
- Muhammad Irfan (ORCID: https://orcid.org/0000-0001-8883-7152)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Liaquat National Hospital (PK)
- Garden City Community College (US)
- Shifa Tameer-e-Millat University (PK)
Publication Details
- Journal
- The Breast Journal
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/tbj/8856567
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00